Zymeworks Inc. (ZYME): Capital Expenditures
$1.52M
Year ended 2025-12-31
$1.21M
Trailing 12 months to 2026-06-30
-42.9%
3-year compound annual growth
-18.8%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.52M | -23.6% | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $1.99M | -19.5% | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $2.47M | -69.6% | 2026-03-02, From 2023-01-01 |
| 2022-12-31 | $8.15M | -34.3% | 2025-03-05, From 2022-01-01 |
| 2021-12-31 | $12.40M | +187.8% | 2024-03-06, From 2021-01-01 |
| 2020-12-31 | $4.31M | n/a | 2023-03-07, From 2020-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Zymeworks Inc. (ZYME) | 2025-12-31 | $1.52M | -23.6% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $835.0K | n/a |
| Theravance Biopharma, Inc. (TBPH) | 2025-12-31 | $42.0K | -87.3% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $289.0K | -2.0% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $1.19M | -48.6% |
| Xencor Inc (XNCR) | 2025-12-31 | $3.15M | -48.3% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $24.81M | +535.1% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $13.41M | -27.1% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $8.30M | -0.6% |
Compare ZYME, ZVRA, TBPH, URGN side by side · Screen every company in Pharmaceutical Preparations ↗